ICML 2019 | Acalabrutinib in ibrutinib-intolerant CLL patients: opening new doors

Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the Phase II study (NCT02717611) of acalabrutinib in ibrutinib-intolerant chronic lymphocytic leukemia (CLL) patients, and the potential implications of this data. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.